Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 3

Ciddi, dirençli, öldürücü, kazanılmış aplastik aneminin klinik seyrine E uygulamasının katkısı

Significance of neuropilin-1 expression in acute myeloid leukemia

Pages
300–306
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Neuropilin-1 can be used as a tool for diagnosis and prognosis in AML patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Neuropilin-1 is a vascular endothelial growth factor receptor that acts as a mediator of angiogenesis.
📊
Key Findings & Data:The aim of this study was to evaluate the significance of neuropilin-1 expression in AML patients by both flow cytometry and real-time polymerase chain reaction (PCR) in regard to its diagnostic and prognostic values.
💡
Conclusion & Impact:Conclusion: Neuropilin-1 can be used as a tool for diagnosis and prognosis in AML patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Neuropilin-1 is a vascular endothelial growth factor receptor that acts as a mediator of angiogenesis. Its importance in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. The aim of this study was to evaluate the significance of neuropilin-1 expression in AML patients by both flow cytometry and real-time polymerase chain reaction (PCR) in regard to its diagnostic and prognostic values. Materials and Methods: Bone marrow aspirates of 44 patients with de novo AML and 12 relapsed AML patients were examined in this study. Ten subjects with nonhematological malignancy serving as the control group were also included. Results: Neuropilin-1 expression by flow cytometry showed a highly significant increase in de novo and relapsed AML patients with a mean of 27.1±17.5% and 21.5±16.6%, respectively, compared to control group’s mean of 3.4±1.9%. A cut-off value of 6% was established as differentiating patients from the control group. By real-time PCR, no statistical significance was found in de novo and relapsed AML patients with a mean of 1.9±3.6 IU/L and 0.3±0.2 IU/L, respectively, compared to the control group’s mean of 0.3±0.1 IU/L. Neuropilin-1 surface expression by flow cytometry showed a significant correlation with total leukocyte count and a negative correlation with hemoglobin level in de novo AML patients. In relapsed AML patients, positive significant correlations were found with age, bone marrow blast percentage, and CD14. Neuropilin-1 mRNA level by real-time PCR showed a positive significant correlation with peripheral blood blast percentage and CD117 and a negative correlation with hemoglobin level in de novo AML patients. In relapsed patients, a positive correlation was found with lactate dehydrogenase. Conclusion: Neuropilin-1 can be used as a tool for diagnosis and prognosis in AML patients.

Özet

Amaç: Neuropilin-1 anjiyogenez mediatörü olarak rol oynayan vasküler endotelyal büyüme faktörü reseptörüdür. Akut miyeloid lösemi (AML) gibi hematolojik malignitelerdeki önemi tam aydınlatılamamıştır. Bu çalışmanın amacı; AML hastalarındaki hem akım sitometri hem de gerçek-zamanlı polimeraz zincir reaksiyonu (PZR) ile ile tanısal ve prognostik değerleri göz önünde bulundurularak değerlendirilmesidir. Gereç ve Yöntemler: Bu çalışmada 44 de novo AML ve relaps olmuş 12 hastanın kemik iliği aspiratları incelendi. Hematoloji dışı malignitesi olan 10 kişinin örnekleri de kontrol grubu olarak dahil edildi. Bulgular: Akım sitometri ile saptanan neuropilin-1 sunumu, de novo ve relaps AML hastalarında, sırasıyla, ortalama %27.1±17.5 ve %21.5±16.6 bulundu ve kontrol grubuna (ortalama %3.4±1.9) göre son derece anlamlı artış gösterdi. Hastalardan kontrol grubunu ayırmada cut-off değeri %6 olarak belirlenmiştir. Gerçek-zamanlı PZR ile saptanan neuropilin-1 sunumu de novo ve relaps AML hastalarında, sırasıyla, ortalama 1.9 ±3.6 IU/L ve 0.3±0.2 IU/L bulundu ve bu değerler kontrol grubuna (ortalama 0.3±0.1 IU/L) göre istatistiksel olarak anlamlı değildi. De novo AML hastalarında akım sitometri ile saptanan neuropilin-1 yüzey sunumu, toplam lökosit sayısı ile anlamlı korelasyon ve hemoglobin düzeyi ile negatif korelasyon göstermekteydi. Relaps AML hastalarında ise yaş, kemik iliğindeki blast oranı ve CD14 ile aralarında anlamlı korelasyon bulunmuştur. De novo AML hastalarında gerçek- zamanlı PZR ile bakılan neuropilin-1 mRNA düzeyi, periferik kandaki blast yüzdesi ve CD117 ile pozitif anlamlı korelasyon, hemoglobin düzeyi ile de negatif korelasyon göstermiştir. Relaps hastalarda laktat dehidrogenaz ile pozitif korelasyon bulunmuştur. Sonuç: Neuropilin-1, AML hastalarında tanı ve prognozda bir araç olarak kullanılabilir.

🔖

Cite This Article

SALLAM, H. T., TELBANY, M. A. S. E. E., MAHMOUD, M. H., ISKANDER, A. M. (2013). Ciddi, dirençli, öldürücü, kazanılmış aplastik aneminin klinik seyrine E uygulamasının katkısı. Turkish Journal of Hematology, Cilt: 30 - Sayı: 3, 300–306. https://ajindex.com/articles/412854

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U, Valent P. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007;48:1997-2007
  2. Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000;89:167-171
  3. Lu L, Zhang L, Xiao Z, Lu S, Yang R, Han ZC. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 2008;49:331-338
  4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
  5. Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci 2005;10:1581- 1596
  6. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, Arsic N, Tafuro S, Sinagra G, Giacca M. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 2008;118:2062- 2075
  7. Schuch G, Machluf M, Bartsch G Jr, Nomi M, Richard H, Atala A, Soker S. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002;100:4622- 4628
  8. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163
  9. Kreuter M, Steins M, Woelke K, Buechner T, Berdel WE, Mesters RM. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide. Eur J Haematol 2007;79:392-397
  10. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007;212:237-248
  11. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S, Sill H, Hoefler G. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004;23:894-904
  12. Bradstock K, Matthews J, Benson E, Page F Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994;84:1220-1225
  13. Wimazal F Sperr WR, Kundi M, Vales A, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Valent P. Prognostic significance of serial determinations of lactate dehydrog